Brian Mehling, M.D. addresses developments in stem cell research
Brian Mehling, M.D., CMO of Blue Horizon International was a featured speaker at a joint annual meeting sponsored by IsraStem and ISCS (Israel Stem Cell Society).
Dr. Mehling spoke on the commercialization of stem cells and was joined by colleagues from across the globe. The conference and exhibition was held April 5-6 at the David Intercontinental Hotel in Tel Aviv.
Leading researchers from academia, industry, and hospitals presented their recent achievements in technologies and clinical studies discussing their most exciting developments. The program included basic science and translational sessions in fields such as cardiovascular, cerebrospinal, diabetes, metabolic and hematological diseases, immunotherapy and reconstructive surgery along with sessions on regulatory and production challenges and commercialization.
Stem cell research, or regenerative medicine research, holds enormous promise for the future advancement of medical care. A tremendous growth has been observed in last decade in stem cell research.
“Phase I clinical trials are the first step toward the commercialization of therapeutic products for humans. Mesenchymal stem cells (MSCs) especially have a promising future in the world of clinical medicine and the number of clinical trials has been rising since the last decade,” said Dr. Mehling.
The cost-effectiveness analysis of stem cells should be explored and discussed and this analysis can only be made once the efficacy of MSC therapy has become clear.
“Our research studies are designed to measure the safety and efficacy of intravenous, intra-articular, and intrathecal stem cell treatments. Comprehensive stem cell protocols employ well-targeted combinations of autologous bone marrow stem cells, autologous adipose stem cells, and allogeneic human umbilical cord mesenchymal stem cells that treat various conditions such as spinal cord injury, traumatic brain injury, and chronic inflammation,” he continued.
Blue Horizon International, LLC is a healthcare consulting company with a unique concept that combines treatment, research, and philanthropy. BHI provides the highest quality care and service available in surgical and medical treatments globally, the most advanced technologies currently available in areas such as stem cell therapy, regenerative medicine, and also provides resources for those who are medically underserved. For more information, please visit www.bluehorizoninternational.com